ARTICLE | Emerging Company Profile
Adcytherix: Emergence team reunites for another ADC company
French biotech to pursue novel targets with ADCs incorporating new and old payloads
June 11, 2024 10:47 PM UTC
The management team behind Emergence Therapeutics is teaming up to launch a second ADC company, Adcytherix, less than a year after the acquisition of its first. This time, the focus isn’t on developing a new ADC platform, but on case-by-case optimization of payloads and targets.
Jack Elands, Xavier Preville and Carsten Dehning, Emergence co-founders and CFO, respectively, began working on Adcytherix S.A.S. with Pontifax Venture Capital just months after Emergence was acquired by Eli Lilly and Co. (NYSE:LLY) last year...